tbuckley/cabot-search huggingface dataset:
Identification of interacting proteins with HPV18E7 using yeast two hybrid system
Authors: Yuji Yaginuma, Masahiro Yamamoto, Masumi Yoshie, Yoshihiro Tokusashi, Susumu Tamakawa, Katsuhiro Ogawa
Journal: Cancer Research (2004)

4765  Human papillomaviruses (HPVs) have been linked to a variety of human diseases, most notably cancer of the cervix, a disease responsible for at least 200,000 death per year worldwide. Over 100 different types of HPV have been identified, and approximately 20 are specific for lesions of the anogenital tract. The latter HPVs are divided into two groups; low-risk group HPVs such as HPV6 and 11 that are associated with benign proliferative lesions, and high-risk group HPVs such as HPV16 and18 that are associated with malignant tumors. The majority of cervical cancers harbor high-risk HPV sequences. These HPVs encode two transforming genes, E6 and E7, both of which are consistently expressed in HPV-positive cervical carcinomas. However, although the biochemical functions of E6 and E7 are thought to be related to the oncogenic potential of HPVs, precise mechanism of carcinogenesis caused by HPVs has not been fully understood. In this study we, therefore, have attempted to analyze the function of HPV18 E7 protein. HPV 18 E7 protein was used for the yeast two-hybrid screen method to isolate interacting proteins. A full-length DNA encoding the HPV18 E7 allele was PCR-amplified (376bp) from HeLa cell DNA, cloned in frame into pDONR201 by BP reaction and transferred into the Destination Vectors pDEST32. Yeast strain Maov203 was transformed with pDEST32-HPV18 E7 and a two-hybrid cDNA libraly (pPC86-human fetal brain cDNA library). After screening 9.5x106 transformants per screen, candidates showing reproducible galactosidase(+) and His(+) phenotype were isolated and grown in SC-Leu-Trp-His+3AT plates to investigate their phenotype. We isolated eleven candidate interacters. Of these, three (Rb, p130 and Dna J protein) were already known to interact with a HPV E7 protein, while eight were novel HPV E7-interacters newly identified in this study. One of the eight proteins is a component of kinetocore. This protein interacted with a high-risk HPV16, 18 and 58 protein but not with a low-risk HPV 4, 6 and 11 E7 protein. Mammalian-two-hybrid assay demonstrated that HPV18 E7 can associate with this candidate protein in CHO-K1 cells in agreement with the yeast-two-hybrid assay. We speculate altered function of this protein may be associated with chromosomal abnormality in high-risk HPV-positive cancer.
Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease
Authors: Casper Steenholdt, Jeppe T. Jensen, Jørn Brynskov, Ann Merete Møller, Anne Christine Limschou, Lars Konge, Peter Vilmann
Journal: Clinical Gastroenterology and Hepatology (2020)
Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I)
Authors: Sherief R. Janmohamed, Martine Grosber, Lawrence F. Eichenfield, Johannes Ring, Jan Gutermuth
Journal: Allergy (2020)

Dr Janmohamed reports personal fees from Pierre Fabre Benelux, outside the submitted work; Dr Grosber has nothing to disclose; Dr Eichenfield reports grants and personal fees from AbbVie, grants and personal fees from Allergan, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Asana BioSciences, grants and personal fees from Dermavant, grants and personal fees from Dermira, Inc, grants and personal fees from DS Biopharma, grants and personal fees from Eli Lilly, grants and personal fees from Forté Pharma, grants and personal fees from Galderma, grants and personal fees from Glenmark, grants and personal fees from Incyte, grants and personal fees from LEO, grants and personal fees from MatriSys, grants and personal fees from Novartis, grants and personal fees from Ortho Dermatologics/Valeant, grants and personal fees from Pfizer, grants and personal fees from Sanofi-Genzyme/Regeneron, and grants and personal fees from UCB Pharma, outside the submitted work; Dr Ring reports personal fees from Sanofi-Genzyme/Regeneron, personal fees from AbbVie, personal fees from LEO, and personal fees from Allergika, outside the submitted work; and Dr Gutermuth reports grants, personal fees and other from Sanofi-Genzyme/Regeneron, personal fees and other from AbbVie, personal fees and other from Lilly, personal fees and other from LEO, personal fees and other from Pfizer, personal fees and other from L'Oreal, and personal fees from Pierre Fabre, outside the submitted work.
TCT CONNECT-246 Drug Coated Balloon (DCB)-Only Angioplasty in De Novo Large Vessel vs. Small Vessel Coronary Disease
Authors: Upul Wickramarachchi, Natasha Corballis, Clint Maart, Sreekumar Sulfi, Trevor Wistow, Alisdair Ryding, Toomas Sarev, Timothy Gilbert, Jane Skinner, Marcus Flather, Simon Eccleshall
Journal: Journal of the American College of Cardiology (2020)
A distinct GM-CSF <sup>+</sup> T helper cell subset requires T-bet to adopt a T <sub>H</sub> 1 phenotype and promote neuroinflammation
Authors: Javad Rasouli, Giacomo Casella, Satoshi Yoshimura, Weifeng Zhang, Dan Xiao, James Garifallou, Michael V. Gonzalez, Alice Wiedeman, Anna Kus, Elisabeth R. Mari, Paolo Fortina, Hakon Hakonarson, S. Alice Long, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami
Journal: Science Immunology (2020)

A GM-CSF + T helper cell subset develops from naïve precursors and switch to a T H 1 phenotype during neuroinflammation.
TCT CONNECT-280 Automatic Characterization of Human Atherosclerotic Plaque Composition From Intravascular Optical Coherence Tomography Using Artificial Intelligence
Authors: Miao Chu, Haibo Jia, Juan Luis Gutiérrez-Chico, Akiko Maehara, Ziad Ali, Xiaoling Zeng, Luping He, Chen Zhao, Mitsuaki Matsumura, Peng Wu, Ming Zeng, Takashi Kubo, Bo Xu, Chen Lianglong, Yu Bo, Gary Mintz, William Wijns, Niels Holm, Shengxian Tu
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-63 Comparative Performance of Bleeding Scores in Patients Older Than 75 Years With Atrial Fibrillation After Percutaneous Coronary Intervention With Drug-Eluting Stents: The PACO-PCI Registry
Authors: Jose De la Torre Hernandez, Ramón López Palop, Soledad Ojeda, José Luis Ferreiro, David Marti, Pablo Avanzas, David Serrano, Alejandro Diego Nieto, Miren Telleria, Ignacio Amat-Santos, Jose Antonio Linares Vicente, Belen Cid Alvarez, Iñigo Lozano, Cristobal Urbano, Marcos Garcia-Guimaraees, Armando Perez de Prado, Felipe Hernandez Guimaraes, Eduardo Pinar Bermudez, Rafael Gonzalez Manzanares, Angel Sanchez Recalde, Ricardo Concepcion, Mario Sadaba, Ignacio Santiago Setien, Andrea Teira
Journal: Journal of the American College of Cardiology (2020)
A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis
Authors: Nitesh Gupta, Pranav Ish, Amitesh Gupta, Nipun Malhotra, Jose Antonio Caminero, Rupak Singla, Rohit Kumar, Siddharth Raj Yadav, Nishanth Dev, Sumita Agrawal, Santvana Kohli, M.K. Sen, Shibdas Chakrabarti, N.K. Gupta
Journal: European Respiratory Journal (2020)

<b>Both tuberculosis and COVID-19 being communicable and prevalent diseases in India, the co-existence can lead to worse outcomes, as seen in this study, where there was high mortality among active as well as treated TB patients with COVID-19 co-infection</b>https://bit.ly/3jHcGbQ
TCT CONNECT-223 Effects of the COVID-19 Pandemic on a Population Older Than 75 Years With Previous Percutaneous Coronary Revascularization: Subanalysis of the SIERRA 75 Registry
Authors: Jose De la Torre Hernandez, Pilar Carrillo, Jesus Jimenez-Mazuecos, Alfonso Freites Esteves, Juan Gabriel Córdoba-Soriano, Alejandro Gutierrez-Barrios, Belen Cid Alvarez, German Calle Perez, Tamara Garcia Camarero, Ramiro Trillo, Armando Perez de Prado, Juan Francisco Oteo Dominguez, Georgina Fuertes Ferre, Victor Alfonso Jimenez Diaz, Iñigo Lozano, Koldobika Garcia San Roman, Raymundo Ocaranza-Sanchez, Gines Martinez Caceres, Juan Sanchis Fores, Sílvio Leal, Xavier Carrillo, Alberto Rodrigues, Mario Sadaba, Imanol Otaegui, Esther Lazaro Fernandez, Jose Antonio Linares Vicente, Francisco J. Morales, Ricardo Santos, Francisco Bosa Ojeda
Journal: Journal of the American College of Cardiology (2020)
Significance of TWEAK/Fn14 pathway in human pancreatic cancer.
Authors: Takahiro Akahori, Masayuki Sho, Takeo Nomi, Satoru Akashi, Naoya Ikeda, Hiromichi Kanehiro, Michiyoshi Hisanaga, Hideo Yagita, Yoshiyuki Nakajima
Journal: Cancer Research (2006)

5724  Tumor Necrosis Factor-like weak inducer of apoptosis (TWEAK) is a newly identified member of the TNF superfamily. Due to its proinflammatory property, it has been suggested to play pivotal roles in various physiological and pathological conditions including autoimmune disorders, atherogenesis and chronic inflammation. The fibroblast growth-inducible 14 (Fn14) has been recently identified as a TWEAK receptor. Several studies have suggested that TWEAK-Fn14 interaction resulted in the promotion of apoptosis, cell growth as well as angiogenesis. Furthermore, recent studies have indicated that TWEAK is expressed in several tumor lines and tissues. They have also demonstrated that TWEAK can stimulate tumor cell apoptosis, proliferation, migration, survival and angiogenesis. In addition, it has been reported that the Fn14 gene is activated during tumorigenesis in several organs including liver, breast and brain. These studies have suggested that TWEAK/Fn14 pathway may be a critical regulator in tumorigenesis. In this study, we tried to clarify the importance of TWEAK/Fn14 pathway in human pancreatic cancer. First, we examined the expression of TWEAK and Fn14 in four human pancreatic cancer cell lines including CAPAN2, PK-8, PANC1 and MIAPaCa2 by RT-PCR analysis. TWEAK was expressed in three lines (CAPAN2, PANC1 and MIAPaCa2) and Fn14 was expressed in all four lines. Then, we examined the expression of TWEAK and Fn14 in human pancreatic cancer tissues. Fifty-one tissues were obtained from surgical cases in our department on patient consent. We performed immunohistochemical analysis on these samples using anti-human TWEAK mAb and anti-human Fn14 mAb. As a result, positive staining for TWEAK was detected in 15 (29%) and positive for Fn14 was detected in 31 (61%). These data suggested that TWEAK and Fn14 might play some role in human pancreatic cancer. Finally, we examined the antitumor effect of TWEAK and Fn14 mAb on tumor growth in vitro. Human pancreatic cancer cells were cocultured with anti-TWEAK mAb, anti-Fn14 mAb or control Ig. By 7 days after coculture, the significant inhibition of tumor growth was observed by mAb treatment. Coculture with anti-TWEAK mAb induced 47–53% cell growth inhibition compared to control Ig (CAPAN2, 47%, MIAPaCa, 53%, PANC1, 47%). Similarly, coculture with anti-Fn14 mAb induced 34–52% inhibition (CAPAN2, 45%, MIAPaCa, 34%, PANC1, 52%). Taken together, TWEAK/Fn14 pathway may be functional and important in pancreatic cancer. In conclusion, we have demonstrated for the first time that TWEAK and Fn14 was expressed in pancreatic cancer and mAb treatment significantly inhibited tumor cell growth in vitro. Thus, TWEAK and/or Fn14 could be novel molecular targets for anti-cancer therapy in human pancreatic cancer.
Management of bacteriological specimens of patients suffering from coronavirus disease 2019 (COVID-19)
Authors: Michael Hogardt, Silke Besier, Lisa Vorbeck, Stephan Göttig, Thomas A. Wichelhaus, David Villinger, Daniel Hack, Julian Sommer, Valentina Ilievski, Volkhard A.J. Kempf
Journal: Clinical Microbiology and Infection (2020)
TCT CONNECT-429 Successive Coronary Catheterization via Distal Transradial Approach in the Same Arm
Authors: Takeshi Yamada, Yuki Matsubara, Soichiro Washimi, Sho Hashimoto, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata, Akihiko Takahashi
Journal: Journal of the American College of Cardiology (2020)
Abstract 11255: Thrombus Risk Prediction in Atrial Fibrillation: Hemodynamic Model of Left Atrial Appendage
Authors: Soroosh Sanatkhani, Prahlad G Menon, Sanjeev G Shroff, Sotirios Nedios
Journal: Circulation (2018)

Introduction: CHADS2 and CHA2DS2-VASc scores are the common measurements to aid decision making for thromboprophylaxis. Any patients with CHA2DS2-VASc score above two is considered high risk for th...
FRI0086 Characterisation of ra33 (hnrnp-a2/b1)- autoreactive t cells in sle-patients
Authors: R Fritsch, D Eselboeck, B Jahn-Schmid, J Neumueller, B Bohle, K Skriner, J Smolen, G Steiner
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> SLE is a systemic autoimmune disease with distinct immunological characteristics including defective T cell functions, especially concerning IL2 production and proliferation. Furthermore, B-cell hyperactivity is observed leading to the formation of several characteristic autoantibodies (ab), among them ab to the heterogenous nuclear ribonucleoprotein A2/B1 (hnRNP/RA33). These antibodies are known to occur in over 20% of SLE patients. <h3>Objectives</h3> In order to elucidate the role of T cells and their influence in antibody production in SLE, we studied proliferation of PBMC to purified hnRNP-A2/B1 in SLE patients and healthy controls. <h3>Methods</h3> Stimulation assays with PBMC of 34 SLE patients and 21 healthy controls were performed. We then proceeded to draw RA33-specific T cell clones (TCC) by cultivation and limiting-dilution cloning of T cell lines. <h3>Results</h3> While the stimulation indices (SI) in the healthy control group ranged from 0.5 to 3.5 (mean SI: 1.5 ± 0.9), the proliferative response of PBMC of the patient group ranged from 0.7 to 17 with a mean SI of 4.8 ± 4.0 (only 6 of 34 patients had an SI &lt;2; p &lt; 0.00004). The generated 30 TCC derived from SLE patients and 19 TCC from healthy controls did not reveal a significant difference in SI and produced either more IFNg than IL4 or none of these cytokines at all, suggesting that these TCC were of T1 or T0, but not T2 phenotype. Interestingly though, while only 11% of healthy control patients showed a CD4-/CD8<sup>+</sup> subtype and 16% displayed a CD4<sup>+</sup>/CD8<sup>+</sup> phenotype, 37% of TCC derived from SLE patients were CD4-/CD8<sup>+</sup> (and 20% expressed CD4 as well as CD8). <h3>Conclusion</h3> Our data reveal that more than 80% of SLE-patients have a significant T cell reactivity (SI &gt;2) to the nuclear protein hnRNP-A2/B1 indicating that the antibody response might be T cell driven. Furthermore, almost 60% of TCC derived from SLE patients were CD8<sup>+</sup>, which supports the importance of these T cells in SLE. Further studies will have to elucidate the pathogenetic implications of these findings.
TCT CONNECT-255 Long-Term Outcome After Coronary Revascularization With Sirolimus-Coated Balloon in Patients With Small-Vessel Disease (≤2.75 mm): 3-Year Results From NANOLUTE Real-World Study
Authors: Bernardo Cortese, Dinesh Shah, Sameer Dani
Journal: Journal of the American College of Cardiology (2020)
Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma
Authors: Dante Descalzi-Montoya, Kira Goldgirsh, Zheng Yang, Eugenia Dziopa, Iriana Colorado, Rena Feinman, Themba Nyirenda, David H. Vesole, Pashna N. Munshi, Scott D. Rowley, Noa Biran, Joshua R Richter, David Siegel, Michele L. Donato, Alan P Skarbnik, Andrew L. Pecora, Robert Korngold
Journal: Blood (2017)
Publisher Correction: Human postprandial responses to food and potential for precision nutrition
Authors: Sarah E. Berry, Ana M. Valdes, David A. Drew, Francesco Asnicar, Mohsen Mazidi, Jonathan Wolf, Joan Capdevila, George Hadjigeorgiou, Richard Davies, Haya Al Khatib, Christopher Bonnett, Sajaysurya Ganesh, Elco Bakker, Deborah Hart, Massimo Mangino, Jordi Merino, Inbar Linenberg, Patrick Wyatt, Jose M. Ordovas, Christopher D. Gardner, Linda M. Delahanty, Andrew T. Chan, Nicola Segata, Paul W. Franks, Tim D. Spector
Journal: Nature Medicine (2020)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
Authors: Faiez Zannad, João Pedro Ferreira, Stuart J. Pocock, Cordula Zeller, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr, Janet Schnee, Christoph Wanner, Milton Packer
Journal: Circulation (2020)

Background: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) hospitalization and total HF hospitalizations, and slowed the progressive decline in kidney function in patients with HF and a reduced ejection fraction, with and without diabetes. We aim to study the effect of empagliflozin on cardiovascular and kidney outcomes across the spectrum of kidney function. Methods: In this prespecified analysis, patients were categorized by the presence or absence of chronic kidney disease (CKD) at baseline (estimated glomerular filtration rate [eGFR] &lt;60 ml/min/1.73 m 2 or albumin-to-creatine ratio &gt;300 mg/g). The primary and key secondary outcomes were: (1) a composite of cardiovascular death or HF hospitalization (primary outcome); (2) total HF hospitalizations; and (3) eGFR slope. The direct impact on kidney events was investigated by a prespecified composite kidney outcome (defined as a sustained profound decline in eGFR, chronic dialysis, or transplant). The median follow-up was 16 months. Results: Of 3730 patients who were randomized to empagliflozin or placebo, 1978 (53%) had CKD. Empagliflozin reduced the primary outcome and total HF hospitalizations in patients with and without CKD: hazard ratio (HR)=0.78 (95% CI, 0.65–0.93) and HR=0.72 (95% CI, 0.58–0.90), respectively (interaction P =0.63). Empagliflozin slowed the slope of eGFR decline by 1.11 (0.23–1.98) ml/min/1.73 m 2 /yr in patients with CKD and by 2.41 (1.49–3.32) ml/min/1.73 m 2 /yr in patients without CKD. The risk of the composite kidney outcome was reduced similarly in patients with and without CKD: HR=0.53 (95% CI, 0.31–0.91) and HR=0.46 (95% CI, 0.22–0.99), respectively. The effect of empagliflozin on the primary composite outcome and key secondary outcomes was consistent across a broad range of baseline kidney function, measured by clinically relevant eGFR subgroups or by albuminuria, including patients with eGFR as low as 20 ml/min/1.73 m 2 . Empagliflozin was well tolerated in CKD patients. Conclusions: In EMPEROR-Reduced, empagliflozin had a beneficial effect on the key efficacy outcomes and slowed the rate of kidney function decline in patients with and without CKD, and regardless of the severity of kidney impairment at baseline. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03057977.
Socioeconomic Disparities Associated With <i>MGMT</i> Promoter Methylation Testing for Patients With Glioblastoma
Authors: Nayan Lamba, Ugonma N. Chukwueke, Timothy R. Smith, Keith L. Ligon, Ayal Aizer, David A. Reardon, J. Bryan Iorgulescu
Journal: JAMA Oncology (2020)

This cohort study evaluates the national practice patterns of MGMT gene testing and identified potential factors associated with access to testing.
TCT CONNECT-459 Transcatheter Aortic Valve Thrombosis: Data From a French Multicenter Cohort Analysis
Authors: Geraud Souteyrand, Thomas Mouyen, Thibaut Manigold, Eric Durand, Thibault Lhermusier, Didier Tchetche, Nicolas Combaret
Journal: Journal of the American College of Cardiology (2020)
Wnt-Dependent Oligodendroglial-Endothelial Interactions Regulate White Matter Vascularization and Attenuate Injury
Authors: Manideep Chavali, Maria José Ulloa-Navas, Pedro Pérez-Borredá, Jose Manuel Garcia-Verdugo, Patrick S. McQuillen, Eric J. Huang, David H. Rowitch
Journal: Neuron (2020)

Recent studies have indicated oligodendroglial-vascular crosstalk during brain development, but the underlying mechanisms are incompletely understood. We report that oligodendrocyte precursor cells (OPCs) contact sprouting endothelial tip cells in mouse, ferret, and human neonatal white matter. Using transgenic mice, we show that increased or decreased OPC density results in cognate changes in white matter vascular investment. Hypoxia induced increases in OPC numbers, vessel density and endothelial cell expression of the Wnt pathway targets Apcdd1 and Axin2 in white matter, suggesting paracrine OPC-endothelial signaling. Conditional knockout of OPC Wntless resulted in diminished white matter vascular growth in normoxia, whereas loss of Wnt7a/b function blunted the angiogenic response to hypoxia, resulting in severe white matter damage. These findings indicate that OPC-endothelial cell interactions regulate neonatal white matter vascular development in a Wnt-dependent manner and further suggest this mechanism is important in attenuating hypoxic injury.
Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer
Authors: Lionel Groussin, Jérôme Clerc, Olivier Huillard
Journal: New England Journal of Medicine (2020)

Restoration of Iodine Uptake with Larotrectinib In a woman with thyroid cancer expressing an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when the capacity of the ...
Therapeutic effect of decellularized extracellular matrix-based hydrogel for radiation esophagitis by 3D printed esophageal stent
Authors: Dong-Heon Ha, Suhun Chae, Jae Yeon Lee, Jae Yun Kim, Jungbin Yoon, Tugce Sen, Sung-Woo Lee, Hak Jae Kim, Jae Ho Cho, Dong-Woo Cho
Journal: Biomaterials (2020)
TCT CONNECT-341 One-Year Clinical Outcomes Following Open Transatrial Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification
Authors: Michael Brener, Estee Hong, Alejandro Pizano, Evan Garner, Matthew Lawlor, Abdallah El Sabbagh, Mayra Guerrero, Raymond Lee, Morgan Harloff, Tsuyoshi Kaneko, Ryan Kaple, David Deaton, Ashequl Islam, Omar Khalique, Michael Borger, James Davies, Kyle Eudailey, Isaac George
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-192 Automated Classification of Computed Tomography Coronary Angiogram as Normal and Abnormal Using High-Sensitivity Deep-Learning Algorithm.
Authors: Prashant Raghav, Sudhir Rathore, Sunil Jain, Sudeep Kumar, Rajneesh Madhok, Samir Rathore
Journal: Journal of the American College of Cardiology (2020)